SG166778A1 - Influenza targets - Google Patents
Influenza targetsInfo
- Publication number
- SG166778A1 SG166778A1 SG201007842-6A SG2010078426A SG166778A1 SG 166778 A1 SG166778 A1 SG 166778A1 SG 2010078426 A SG2010078426 A SG 2010078426A SG 166778 A1 SG166778 A1 SG 166778A1
- Authority
- SG
- Singapore
- Prior art keywords
- influenza
- influenza targets
- targets
- kinases
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85065106P | 2006-10-11 | 2006-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG166778A1 true SG166778A1 (en) | 2010-12-29 |
Family
ID=39203225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG201007842-6A SG166778A1 (en) | 2006-10-11 | 2007-10-11 | Influenza targets |
Country Status (7)
Country | Link |
---|---|
US (1) | US20110150897A1 (fr) |
EP (1) | EP2087110A2 (fr) |
JP (1) | JP2010505897A (fr) |
AU (1) | AU2007306542B2 (fr) |
CA (1) | CA2666185A1 (fr) |
SG (1) | SG166778A1 (fr) |
WO (1) | WO2008043561A2 (fr) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
CA2524255C (fr) | 2003-03-21 | 2014-02-11 | Academisch Ziekenhuis Leiden | Modulation de la reconnaissance d'exons dans le pre-arnm par interference avec la structure d'arn secondaire |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
EP1790664A1 (fr) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Anticorps monoclonaux contre claudin-18 pour le traitement du cancer |
CA2670563A1 (fr) | 2006-11-27 | 2008-06-05 | Isis Pharmaceuticals, Inc. | Procedes pour traiter l'hypercholesterolemie |
US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
AR066984A1 (es) | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
WO2009021150A2 (fr) * | 2007-08-08 | 2009-02-12 | California Pacific Medical Center | Le récepteur du facteur de croissance dérivés des plaquettes tolère l'infectiosité du cytomégalovirus |
WO2009054725A2 (fr) | 2007-10-26 | 2009-04-30 | Academisch Ziekenhuis Leiden | Moyens et procédés pour contrebalancer des troubles musculaires |
USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
WO2009141541A2 (fr) * | 2008-04-22 | 2009-11-26 | Centre National De La Recherche Scientifique | Nouvelles compositions inhibant la melanogenese et leurs utilisations |
EP2119783A1 (fr) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Procédé pour l'omission efficace de l'exon (44) dans la dystrophie musculaire de Duchenne et moyens connexes |
WO2010083615A1 (fr) * | 2009-01-26 | 2010-07-29 | Protiva Biotherapeutics, Inc. | Compositions et procédés d'inactivation de l'expression de l'apolipoprotéine c-iii |
EP2411018A2 (fr) * | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | INHIBITION PAR INTERFÉRENCE ARN DE L'EXPRESSION DU GÈNE DE LA CHAÎNE BÊTA DU FACTEUR DE CROISSANCE DES NERFS (NGFß) AU MOYEN D'UN ACIDE NUCLÉIQUE INTERFÉRENT COURT (ANSI) |
JP2012524540A (ja) | 2009-04-24 | 2012-10-18 | プロセンサ テクノロジーズ ビー.ブイ. | Dmdを処置するためのイノシンを含むオリゴヌクレオチド |
US9238815B2 (en) | 2009-12-11 | 2016-01-19 | Icahn School of Medicine at Mounta Sinai | Compositions and methods for inhibiting human host factors required for influenza virus replication |
EP2516645A1 (fr) | 2009-12-23 | 2012-10-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Cibles de la grippe |
US8906607B2 (en) * | 2010-04-30 | 2014-12-09 | Cellectis | Method for modulating double-strand break-induced homologous recombination |
PT2585596T (pt) | 2010-06-23 | 2021-03-23 | Curna Inc | Tratamento de doenças relacionadas com a subunidade alfa de canais de sódio dependentes de voltagem (scna) por inibição da transcrição antissentido natural para scna |
EP2426216A1 (fr) * | 2010-09-01 | 2012-03-07 | Institut Gustave Roussy (IGR) | Biomarqueurs de pronostic et/ou de prédiction et applications biologiques correspondantes |
GB201018147D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Method of treatment |
JP6073795B2 (ja) * | 2010-10-27 | 2017-02-01 | カッパーアールエヌエー,インコーポレイテッド | インターフェロン関連発生制御因子1(ifrd1)への天然アンチセンス転写物の阻害によるifrd1関連疾患の治療 |
EP2446883A1 (fr) * | 2010-10-30 | 2012-05-02 | University College Cork-National University of Ireland, Cork | Traitement des inflammations |
WO2012075114A2 (fr) * | 2010-12-01 | 2012-06-07 | Ablitech, Inc. | Conjugués acide nucléique-polymère et leurs utilisations |
US9359605B2 (en) | 2011-03-11 | 2016-06-07 | Sarissa Inc. | Method of treating cancer by inhibition of DNA repair proteins |
SG194909A1 (en) * | 2011-05-13 | 2013-12-30 | Agency Science Tech & Res | Compounds and methods for treating insulin resistance syndrome |
SG11201400976WA (en) * | 2011-09-28 | 2014-04-28 | Agency Science Tech & Res | Methods and pharmaceutical compositions for treating cancer |
WO2013112053A1 (fr) | 2012-01-27 | 2013-08-01 | Prosensa Technologies B.V. | Oligonucléotides à modulation d'arn dotés de caractéristiques améliorées pour le traitement de la dystrophie musculaire de duchenne et de becker |
AU2013203395A1 (en) | 2012-03-30 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome |
WO2013157215A1 (fr) * | 2012-04-17 | 2013-10-24 | 国立大学法人山口大学 | Procédé pour estimer la susceptibilité au cancer de l'endomètre |
WO2013167153A1 (fr) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Anticorps utiles dans le diagnostic du cancer |
CN111254145A (zh) | 2013-03-14 | 2020-06-09 | Ionis制药公司 | 用于调节tau表达的组合物和方法 |
TWI772856B (zh) | 2013-07-19 | 2022-08-01 | 美商百健Ma公司 | 用於調節τ蛋白表現之組合物 |
EP2853596A1 (fr) | 2013-09-30 | 2015-04-01 | IKBT (Institut für Klinische Biomedizinische Forschung Thurgau) | Inhibiteur de phosphatase de protéine |
JPWO2015108162A1 (ja) | 2014-01-17 | 2017-03-23 | 協和発酵キリン株式会社 | β2GPIの発現を抑制する核酸 |
JP6663149B2 (ja) * | 2014-07-04 | 2020-03-11 | 国立大学法人高知大学 | 膵がん細胞浸潤転移阻害剤 |
CN113846101A (zh) * | 2014-11-17 | 2021-12-28 | 阿尔尼拉姆医药品有限公司 | 载脂蛋白C3(APOC3)iRNA组合物及其使用方法 |
US20190071668A1 (en) * | 2015-07-08 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of cancer using slncr isoforms |
PT109454A (pt) * | 2016-06-14 | 2017-12-14 | Phyzat Biopharmaceuticals Lda | Ácidos nucleicos de interferência e composições que os compreendem |
JOP20190065A1 (ar) | 2016-09-29 | 2019-03-28 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن tau |
WO2018221649A1 (fr) | 2017-05-31 | 2018-12-06 | 協和発酵キリン株式会社 | Acides nucléiques suppresseurs de l'expression d'apcs |
BR112019023650A2 (pt) | 2017-07-06 | 2020-06-02 | Arrowhead Pharmaceuticals, Inc. | Agentes rnai para inibir a expressão de alfa-enac e métodos de uso |
CN111212909A (zh) * | 2017-10-17 | 2020-05-29 | 箭头药业股份有限公司 | 用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物 |
EP3710587A1 (fr) * | 2017-11-16 | 2020-09-23 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de kisspeptine 1 (kiss1) et leurs méthodes d'utilisation |
SG11202007583SA (en) * | 2018-03-21 | 2020-09-29 | Regeneron Pharma | 17β-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
EP3689896A1 (fr) * | 2019-01-31 | 2020-08-05 | Universität Heidelberg | Arnmi de modulation grk2 |
US20230357774A1 (en) * | 2020-09-29 | 2023-11-09 | Empirico Inc. | Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases |
WO2022103999A1 (fr) * | 2020-11-13 | 2022-05-19 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni du facteur de coagulation v (f5) et leurs procédés d'utilisation |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7067144B2 (en) * | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
BRPI0115814B8 (pt) * | 2000-12-01 | 2021-05-25 | Europaeisches Laboratorium Fuer Molekularbiologie Embl | moléculas de rna de filamento duplo, seu método de preparação e composição farmacêutica compreendendo as mesmas |
DE10138912A1 (de) * | 2001-08-08 | 2003-02-27 | Medinnova Ges Med Innovationen | Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen |
US20030219895A1 (en) * | 2002-05-22 | 2003-11-27 | Isis Pharmaceuticals Inc. | Antisense modulation of CDC-like kinase 1 expression |
US20040242518A1 (en) * | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
US20060160759A1 (en) * | 2002-09-28 | 2006-07-20 | Jianzhu Chen | Influenza therapeutic |
DE10313636A1 (de) * | 2003-03-26 | 2004-10-14 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Verwendung von Wirksubstanzen zur Vorbeuge oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen |
-
2007
- 2007-10-11 AU AU2007306542A patent/AU2007306542B2/en not_active Ceased
- 2007-10-11 EP EP07818923A patent/EP2087110A2/fr not_active Withdrawn
- 2007-10-11 CA CA002666185A patent/CA2666185A1/fr not_active Abandoned
- 2007-10-11 US US12/445,228 patent/US20110150897A1/en not_active Abandoned
- 2007-10-11 WO PCT/EP2007/008852 patent/WO2008043561A2/fr active Application Filing
- 2007-10-11 JP JP2009531778A patent/JP2010505897A/ja active Pending
- 2007-10-11 SG SG201007842-6A patent/SG166778A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2008043561A2 (fr) | 2008-04-17 |
JP2010505897A (ja) | 2010-02-25 |
AU2007306542B2 (en) | 2013-08-01 |
AU2007306542A1 (en) | 2008-04-17 |
EP2087110A2 (fr) | 2009-08-12 |
WO2008043561A3 (fr) | 2008-10-02 |
US20110150897A1 (en) | 2011-06-23 |
CA2666185A1 (fr) | 2008-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG166778A1 (en) | Influenza targets | |
UA99284C2 (ru) | ИНГИБИТОРЫ р70 S6-КИНАЗЫ | |
WO2007095124A3 (fr) | Derives, compositions de benzazole et procedes d'utilisation en tant qu'inhibiteurs de la kinase aurora | |
MY146969A (en) | Dpp iv inhibitor formulations | |
MX2009004716A (es) | Compuestos y composiciones en la forma de inhibidores de quinasa de proteina. | |
MX2009011951A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
JO3002B1 (ar) | مركبات و تركيبات كمثبطات كيناز بروتين | |
MX2009007944A (es) | Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium. | |
ZA200901037B (en) | Pyrimidone compounds as GSK-3 inhibitors | |
PH12015501806B1 (en) | Novel benzopyran kinase modulators | |
MX2009013729A (es) | Imidazopirazinas como inhibidores de proteina quinasa. | |
IL197933A (en) | Knaase inhibitors, pharmaceuticals containing them and their uses | |
EA201101341A1 (ru) | Соединения, ингибирующие киназы, и фармацевтическая композиция на их основе | |
IL192640A0 (en) | Inhibitors of tyrosine kinases and pharmaceutical compositions containing the same | |
MX2009006535A (es) | Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina. | |
MX2009000285A (es) | Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas. | |
MX2009011950A (es) | Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
WO2010006086A3 (fr) | Inhibiteurs de kinases et procédés d'utilisation | |
MY148634A (en) | Pyridazinone derivatives | |
WO2007115289A8 (fr) | Combinaisons d'agents thérapeutiques destinées à traiter le cancer | |
PH12013502370A1 (en) | Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
TN2011000207A1 (en) | Akt and p70 s6 kinase inhibitors | |
WO2009114461A3 (fr) | Formes pharmaceutiques d'angiotensine (1-7) et leur utilisation | |
MX2009011952A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
CL2008000021A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer. |